TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT00795639

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

Cause of deathSafety Automatic label, confidence 0.9, unverified. How labels are made.
“Safety Issue: The trial was prematurely terminated on Dec 9, 2010, due to safety concerns, specifically new emerging evidence of hepatic injury.”

The sponsor’s own words in the registry.

Life of this trial

200820092010201120122013Registered2008-11-20Started2008-12Stopped2011-03Results posted2012-03-01

Vital statistics

Status
Terminated
Phase
Phase 3
Sponsor
Pfizer
Sponsor type
Industry
Conditions
Pulmonary Arterial Hypertension; Pulmonary Hypertension
Interventions
Sitaxsentan; Placebo
Participants
183
Sites
85
Countries
Argentina, Bulgaria, Chile, China, Colombia, Costa Rica, Czechia, Dominican Republic, Guatemala, India, Malaysia, Mexico and more

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.